Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent. According ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. “Over the past decade, demand for ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

Allurion Technologies (ALUR) announced topline results from the AUDACITY FDA pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...